Clinical Trials

Accrual Status
Limit to SWOG Trials

1027 Results

    View
    Status Trial Number Title Activated Closed Accrual Phase Published
    Closed S0505 Soft Tissue Sarcomas 3/1/2006 68% Published
    Closed S0434 Phase II Relapsing/Resistant Myeloma Previously Treated with Bortezomib 3/15/2006 58% Published
    Closed S0521 Phase III Maint. vs. Obs. for Low and Intermediate Risk APL 6/1/2007 19% Published
    Closed S0535 Phase II ATRA, Arsenic and Mylotarg for Untreated High-Risk APL 11/15/2007 100%
    Closed S0629 Observational and Phase II WM w/ Trans. & Maint. for Symptomatic WM 9/15/2008 0%
    Closed S0711 Dasatinib in patients with impaired hepatic function 10/15/2008 100%
    Closed S0703 Phase II Older Previously Untreated Non-M3 AML 12/1/2008 93% Published
    Closed S0805 Phase II HyperCVAD + Dasatinib with or without Allo SCT for Ph+ ALL 9/1/2009 100% Published
    Closed S1007 ADJUVANT: Phase III Randomized Endocrine Therapy +/- Chemo according to RS 1/15/2011 100%
    Closed S0820 Adenoma (and Second Primary) Prevention Trial 3/1/2013 91%
    Closed S1200 Randomized trial with acupuncture for joint symptoms related to AIs in women with early stg brst ca 3/27/2012 99%
    Closed S1211 PII Optimal Induction for HRMM 10/12/2012 100%
    Closed S1221 BRAF Mutant Metastatic Cancer 7/1/2013 39%
    Closed S1313 Ph Ib/II Rando mFOLFIRINOX+PEGPH20 vs mFOLFIRINOX Alone in Good PS Met Pancreatic Adenocarcinoma 1/6/2014 73%
    Closed S1400 Lung Master Protocol Advanced Squamous Cell NSCLC 6/15/2014
    Closed S1400C Lung-MAP S1400C: CDK4/6 - Palbociclib 6/15/2014 91%
    Closed S1316 Surgery vs Non-Surgical Management for MBO 3/9/2015 100%
    Closed S1505 Perioperative FOLFIRINOX vs Gem/nab-Pac for Resectable Panc Adeno 10/12/2015 98%
    Closed S1404 MK-3475, Interferon, Resected High-Risk Melanoma 10/15/2015 98%
    Closed S1415CD Trial Assessing CSF Prescribing, Effectiveness and Risk (TRACER) 10/7/2016 93%
    Scroll Table